Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

por Finn, Richard S., Aleshin, Alexey, Slamon, Dennis J.
Publicado 2016

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation

por Wu, Yanyuan, Alvarez, Monica, Slamon, Dennis J, Koeffler, Phillip, Vadgama, Jaydutt V
Publicado 2010

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

por Lu, Nu T., Raizer, Jeffrey, Gabor, Erwin P., Liu, Natalie M., Vu, James Q., Slamon, Dennis J., Barstis, John L.
Publicado 2015

Clinical evaluation of BCL-2/X(L) levels pre- and post- HER2-targeted therapy

por Zoeller, Jason J., Press, Michael F., Selfors, Laura M., Dering, Judy, Slamon, Dennis J., Hurvitz, Sara A., Brugge, Joan S.
Publicado 2021

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

por Wander, Seth A, O’Brien, Neil, Litchfield, Lacey M, O’Dea, Declan, Morato Guimaraes, Claudia, Slamon, Dennis J, Goel, Shom
Publicado 2022

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

por Britten, Carolyn D, Gomes, Antoinette S, Wainberg, Zev A, Elashoff, David, Amado, Rafael, Xin, Yan, Busuttil, Ronald W, Slamon, Dennis J, Finn, Richard S
Publicado 2012

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

por Fejzo, Marlena S., Anderson, Lee, von Euw, Erika M., Kalous, Ondrej, Avliyakulov, Nuraly K., Haykinson, Michael J., Konecny, Gottfried E., Finn, Richard S., Slamon, Dennis J.
Publicado 2013

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-posit...

por Hurvitz, Sara A, Bosserman, Linda D, Chan, David, Hagenstad, Christopher T, Kass, Frederick C, Smith, Frederick P, Rodriguez, Gladys I, Childs, Barrett H, Slamon, Dennis J
Publicado 2014

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition

por Campos, Maira P., Cohen, Melissa, Von Euw, Erika, Velculescu, Victor, Kujak, Jennifer L., Conklin, Dylan, Hallberg, Dorothy, Slamon, Dennis J., Elvin, Julia, Konecny, Gottfried E.
Publicado 2018

HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells

por Wilson, Cindy A, Cajulis, Elaina E, Green, Jennifer L, Olsen, Taylor M, Chung, Young Ah, Damore, Michael A, Dering, Judy, Calzone, Frank J, Slamon, Dennis J
Publicado 2005

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

por Finn, Richard S, Dering, Judy, Conklin, Dylan, Kalous, Ondrej, Cohen, David J, Desai, Amrita J, Ginther, Charles, Atefi, Mohammad, Chen, Isan, Fowst, Camilla, Los, Gerret, Slamon, Dennis J
Publicado 2009

Role for polo-like kinase 4 in mediation of cytokinesis

por Press, Michael F., Xie, Bin, Davenport, Simon, Zhou, Yu, Guzman, Roberta, Nolan, Garry P., O’Brien, Neil, Palazzolo, Michael, Mak, Tak W., Brugge, Joan S., Slamon, Dennis J.
Publicado 2019

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III stu...

por de Haas, Sanne L., Slamon, Dennis J., Martin, Miguel, Press, Michael F., Lewis, Gail D., Lambertini, Chiara, Prat, Aleix, Lopez-Valverde, Vanesa, Boulet, Thomas, Hurvitz, Sara A.
Publicado 2023

Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum

por Fejzo, Marlena S., Sazonova, Olga V., Sathirapongsasuti, J. Fah, Hallgrímsdóttir, Ingileif B., Vacic, Vladimir, MacGibbon, Kimber W., Schoenberg, Frederic P., Mancuso, Nicholas, Slamon, Dennis J., Mullin, Patrick M.
Publicado 2018

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

por McDermott, Martina S. J., Browne, Brigid C., Conlon, Neil T., O’Brien, Neil A., Slamon, Dennis J., Henry, Michael, Meleady, Paula, Clynes, Martin, Dowling, Paul, Crown, John, O’Donovan, Norma
Publicado 2023

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

por McDermott, Martina SJ, Browne, Brigid C, Conlon, Neil T, O’Brien, Neil A, Slamon, Dennis J, Henry, Michael, Meleady, Paula, Clynes, Martin, Dowling, Paul, Crown, John, O’Donovan, Norma
Publicado 2014

A careful reassessment of anthracycline use in curable breast cancer

por Hurvitz, Sara Alsterlind, McAndrew, Nicholas P., Bardia, Aditya, Press, Michael F., Pegram, Mark, Crown, John P., Fasching, Peter A., Ejlertsen, Bent, Yang, Eric H., Glaspy, John A., Slamon, Dennis J.
Publicado 2021

FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells

por Bernardo, Gina M., Bebek, Gurkan, Ginther, Charles L., Sizemore, Steven T., Lozada, Kristen L., Miedler, John D., Anderson, Lee A., Godwin, Andrew K., Abdul-Karim, Fadi W., Slamon, Dennis J., Keri, Ruth A.
Publicado 2012

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

por Diéras, Véronique, Rugo, Hope S, Schnell, Patrick, Gelmon, Karen, Cristofanilli, Massimo, Loi, Sherene, Colleoni, Marco, Lu, Dongrui R, Mori, Ave, Gauthier, Eric, Huang Bartlett, Cynthia, Slamon, Dennis J, Turner, Nicholas C, Finn, Richard S
Publicado 2018

Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 a...

por Finn, Richard S., Cristofanilli, Massimo, Ettl, Johannes, Gelmon, Karen A., Colleoni, Marco, Giorgetti, Carla, Gauthier, Eric, Liu, Yuan, Lu, Dongrui R., Zhang, Zhe, Bartlett, Cynthia Huang, Slamon, Dennis J., Turner, Nicholas C., Rugo, Hope S.
Publicado 2020